Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease

被引:2
作者
Visser, Otto J.
Perk, Lars R.
Zijlstra, Josee M.
van Dongen, Guus A. M. S.
Huijgens, Peter C.
van de Loosdrecht, Arjan A.
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-1081 HV Amsterdam, Netherlands
关键词
D O I
10.2165/00063030-200620040-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radioimmunotherapy (RIT) is a new treatment modality that combines the benefits of radiotherapy and immunotherapy. In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells. Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL), Clinical experience with RIT in the treatment of patients with indolent NHL is increasing. To date, two commercially available agents are used: yttrium-90 (Y-90)-ibritumomab tiuxetan and iodine-131 (I-131)-tositumomab. In general, there is no organ-specific non-hematologic toxicity when a standard dose of RIT is used. Bone marrow suppression is the dose-limiting RIT toxicity; therefore, bone marrow infiltration by NHL should be investigated before treatment. Treatment-related myelodysplastic syndromes and acute myeloid leukemia after RIT are being investigated but long-term data are needed for final evaluation. Results are quite encouraging with respect to complete remission and overall response, even in pretreated patients with unconjugated monoclonal antibodies. RIT induces high response rates and a significant subgroup of patients has achieved long-term durable responses. RIT is feasible in heavily pretreated patients and does not compromise future treatments in the event of progressive disease. Randomized phase III studies are in progress to evaluate the timing of RIT in the overall management of indolent NHL Investigations of new emerging therapeutic strategies for patients with indolent NHL are underway, with research into the feasibility of RIT as first-line therapy and in advanced disease, RIT dose escalation and combined modality approaches with autologous stem cell transplantation. The encouraging results of RIT in indolent NHL have initiated studies focusing on its benefit for patients with aggressive NHL.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 42 条
  • [1] Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
    Advani, R
    Rosenberg, SA
    Horning, SJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1454 - 1459
  • [2] Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature
    Ansell, SM
    Schilder, RJ
    Pieslor, PC
    Gordon, LI
    Emmanouilides, C
    Vo, K
    Czuczman, MS
    Witzig, TE
    Theuer, C
    Molina, A
    [J]. CLINICAL LYMPHOMA, 2004, 5 (03): : 202 - 204
  • [3] Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Ansell, SM
    Ristow, KM
    Habermann, TM
    Wiseman, GA
    Witzig, TE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3885 - 3890
  • [4] Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    Bennett, JM
    Kaminski, MS
    Leonard, JP
    Vose, JM
    Zelenetz, AD
    Knox, SJ
    Horning, S
    Press, OW
    Radford, JA
    Kroll, SM
    Capizzi, RL
    [J]. BLOOD, 2005, 105 (12) : 4576 - 4582
  • [5] Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients
    Börjesson, PKE
    Jauw, YWS
    Boellaard, R
    de Bree, R
    Comans, EFI
    Roos, JC
    Castelijns, JA
    Vosjan, MJWD
    Kummer, JA
    Leemans, CR
    Lammertsma, AA
    van Dongen, GAMS
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2133 - 2140
  • [6] Radioimmunotherapy of non-Hodgkin lymphomas
    Cheson, BD
    [J]. BLOOD, 2003, 101 (02) : 391 - 398
  • [7] CZUCZMAN M, 2005, AM SOC HEMATOL, P1386
  • [8] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
  • [9] Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Fisher, RI
    Kaminski, MS
    Wahl, RL
    Knox, SJ
    Zelenetz, AD
    Vose, JM
    Leonard, JP
    Kroll, S
    Goldsmith, SJ
    Coleman, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7565 - 7573
  • [10] High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
    Gopal, AK
    Rajendran, JG
    Petersdorf, SH
    Maloney, DG
    Eary, JF
    Wood, BL
    Gooley, TA
    Bush, SA
    Durack, LD
    Martin, PJ
    Matthews, DC
    Appelbaum, FR
    Bernstein, ID
    Press, OW
    [J]. BLOOD, 2002, 99 (09) : 3158 - 3162